Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSI...

2024-12-18 08:00 1402

Complete Genomics Adds Eurofins Clinical Enterprise, LLC to its Sequencing Service Provider Program

FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical Enterprise, LLC as the newest addition to its Sequencing Service Provider Program. Complete Genomics'...

2024-12-17 22:00 814

Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

Agreement to Deliver Critical Medicines ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on theAsia-Pacific market is pleased to announce that Hupan Phar...

2024-12-17 21:30 1456

Xinhua Silk Road: Why is Pien Tze Huang selected as one of China's brands favored by foreigners in 2024

BEIJING, Dec. 17, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang), a time-honored Chinese enterprise mainly engaging in pharmaceutical manufacturing, was selected as one of China's brands favored by foreigners in 2024 at the 2024 China Brand Day gala held i...

2024-12-17 20:40 1831

Great Bay Bio Completes First Close of Series B Financing

HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble A...

2024-12-17 16:42 1179

Great Bay Bio Completes First Close of Series B Financing

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Ad...

2024-12-17 11:48 1913

SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals

SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and ef...

2024-12-17 08:20 1122

Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...

2024-12-17 07:51 1234

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and over 70% of patients in TANDEM (Fixed Do...

2024-12-16 22:08 1525

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...

2024-12-16 20:03 872

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique globalclinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundan...

2024-12-16 10:30 1599

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

SAN FRANCISCO and SUZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-12-16 07:55 2206

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Bushu Pharma's ongoing investments and efforts offer customers state-of-the-art capabilities, increased capacity, and innovative solutions, providing top-tier pharmaceutical manufacturing and supply chain management services. SAN ANTONIO, Dec. 15, 2024 /PRNewswire/ -- Frost & Sullivan researched ...

2024-12-15 13:30 1831

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC...

2024-12-13 10:35 2167

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 1392

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 1512

CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...

2024-12-12 21:00 1326

Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.

CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences"). Porton will provide comprehensi...

2024-12-12 21:00 1409

Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...

2024-12-12 21:00 1675

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

Xinhua Silk Road: Pien Tze Huang boosts TCM globalization

BEIJING, Dec. 12, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., aFujian-based traditional Chinese medicine (TCM) company, has been striving to expand its overseas markets, enhancing the influence of TCM in regions such asSoutheast Asia and Europe. Committed to deepening...

2024-12-12 20:43 1805

1 234 5 6 ... 318